The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2017 | What are the practical considerations for monoclonal antibody infusion?
Torben Plesner, MD, from the Vejle Hospital and University of Southern Denmark, Vejle, Denmark, discusses practical management of monoclonal antibody infusion at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. He explains that for the monoclonal antibody daratumumab, few infusion side effects are seen, and explains what should be done if nasal congestion is observed during the infusion and when the infusion can be resumed. Prof. Plesner gives an overview of the expected infusion times for the first infusion and subsequent infusions, and mentions a new subcutaneous formulation of daratumumab which is being developed.
